News

/News
News2019-03-13T15:06:39+00:00

Latest News

Linnaeus Therapeutics Closes $4.4 Million Series A Financing

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that it has closed a $4.4 million series A financing. Kairos Ventures, of Beverly Hills, California, led the financing with significant participation from the University of Pennsylvania, Linnaeus CEO, Patrick Mooney, and Linnaeus SVP, R&D, Tina Garyantes.

Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Melanoma Data

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that preclinical data from studies conducted at the University of Pennsylvania by its scientific founders was published in the journal eLife.

We Listen to the Clinical Experience

We allow it to inform the science that drives the development of new treatments to treat cancer.

Contact Us